Watch out GSK and AstraZeneca! Here comes a new asthma combo!
Novartis has entered into a global collaboration with Schering-Plough to develop and commercialize a novel once-daily inhaled fixed-dose combination therapy for the treatment of asthma and chronic obstructive pulmonary disease (COPD).
The goal is to develop a new therapy that would combine the therapeutic benefits of the once daily long and fast acting Beta2-agonist QAB149 (indacaterol) of Novartis and Schering-Plough's once-daily oral corticosteroid mometasone (Asmanex) in a single inhalation device.
This deal follows on the heels of AZ and Abbott announcing they would work together more closely in The Statin Wars with "Project Crestorin".
Could this be a new trend emerging, Insider wonders? Big Pharma's dating....... perhaps to check each other out prior to marriage?
No comments:
Post a Comment